Nebivolol Viatris (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Viatris, is a beta‑blocker presented as an oral tablet for oral use. It treats hypertension and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Nebivolol Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic receptor antagonist used in cardiovascular disease management.

Hypertension: lowers systemic blood pressure and reduces cardiovascular risk. Heart failure (reduced ejection fraction): improves ventricular function and decreases hospitalization rates.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache - Dizziness - Fatigue - Bradycardia - Nausea - Nasal congestion

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Acute bronchospasm in susceptible individuals - Allergic skin reactions or angioedema - Hepatic enzyme elevations - Syncope

Before initiating therapy, consider the following safety measures.

Monitor blood pressure: ensure adequate control without excessive drop. Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. Use caution in asthma or chronic obstructive pulmonary disease: β‑blockade may exacerbate bronchospasm. Review concomitant beta‑blocker use: avoid additive effects. Adjust in hepatic impairment: dose may need modification. Store at ambient temperature: keep in the original container, protect from moisture.

Nebivolol can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects. - Calcium‑channel blockers (verapamil, diltiazem): risk of AV‑block and severe bradycardia. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma levels. - Clonidine abrupt withdrawal: may precipitate rebound hypertension. - Insulin or oral hypoglycemics: may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate antihypertensive efficacy. - Diuretics: heightened risk of orthostatic hypotension. - Digoxin: potential for enhanced bradycardia. - Other antihypertensives: monitor for additive blood pressure lowering. - Antidepressants (serotonergic agents): watch for QT prolongation.